The market for initial public offerings in the US looks like it might be waking up from a month and a half nap with one biopharmaceutical company making it through the IPO window in mid-June and three others filing to go public with more sizeable offerings. Also, Galderma S.A. – a large privately held, commercial-stage, dermatology-focused firm – has signaled that it may pursue an IPO soon.
Azitra Inc., which is developing precision dermatology therapeutics using engineered proteins and topical live biotherapeutic products, grossed $7.5m when...